News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Altor BioScience Corporation In-Licenses Tissue Factor Antagonists from Genentech, Inc. (DNA)


2/12/2008 8:43:00 AM

MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor) announced today it has entered into an agreement with Genentech, Inc. for exclusive, worldwide rights to develop and commercialize a class of antibody-based Tissue Factor antagonists. Altor plans on initiating a multi-center, Phase II clinical study later this year, using the lead therapeutic antibody known as ALT-836 for the treatment of Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI). Financial terms of the licensing transaction were not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES